04:07 PM EDT, 05/03/2024 (MT Newswires) -- Johnson & Johnson ( JNJ ) said Friday that its latest Phase 2 Apa-RP study on Erleada and ADT combination therapy in post-radical prostatectomy patients with high-risk localized prostate cancer showed a 100% biochemical recurrence-free rate at 24 months.

The Apa-RP study, which met its primary endpoint, assessed high-risk localized prostate cancer patients post-radical prostatectomy. Results revealed a 100% BCR-free rate at 24 months after initiating the combination treatment, indicating no increase in prostate-specific antigen levels.

The treatment regimen showed a serum testosterone recovery rate of 76.4% at 12 months, the company said.